Related Experiment Video

Updated: May 2, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.1K

Oncolytic immunotherapy: where are we clinically?

Akseli Hemminki1

  • 1Cancer Gene Therapy Group, Haartman Institute, University of Helsinki, Haartmaninkatu 3, 00290 Helsinki, Finland ; TILT Biotherapeutics Ltd., P. Hesperiankatu 37A22, 00260 Helsinki, Finland.

Scientifica
|February 20, 2014
PubMed

Insights

Oncolytic viruses show promise in cancer treatment, with human trials revealing significant immunostimulatory effects. Further research is needed to understand the mechanisms of action and optimize their use in cancer immunotherapy.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Oncolytic viruses have a long history of research, now advancing to phase 3 clinical trials.
  • Human data suggests oncolytic viruses possess strong immunostimulatory properties.
  • The precise mechanisms driving antitumor immunity from oncolysis are not fully elucidated.

Purpose of the Study:

  • To review available clinical data on oncolytic viruses.
  • To emphasize the immunological aspects of oncolytic virus therapy.
  • To explore the contributions of oncolysis, immune response, and transgenes to treatment efficacy.

Main Methods:

  • Review of existing clinical trial data for oncolytic viruses.
  • Analysis of human data focusing on immunological responses.
  • Comparison of different oncolytic virus types (adenovirus, herpes, reo, vaccinia).

Main Results:

  • Oncolytic viruses are demonstrating efficacy in phase 3 trials.
  • Significant immunostimulatory activity observed in human subjects.
  • Safety and efficacy profiles appear promising across various virus types.

Conclusions:

  • The induction of antitumor immunity is a key consequence of oncolytic virus therapy.
  • Understanding the interplay between oncolysis, immune response, and transgenes is crucial.
  • Further mechanistic studies using human data are required to optimize oncolytic virotherapy.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

8.9K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

7.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.0K